Fast Forward Therapeutic Innovation
March 17, 2026
Avanti Biosciences has been named a Connect San Diego 2026 Cool Company, recognized among San Diego's most promising venture-ready startups. Connect's Cool Companies program has supported over 100 companies since 2015, which have collectively raised more than $1 billion in funding. Avanti will participate in a series of showcase events, including a Private VC Showcase on April 15, 2026, and a Public Showcase on June 16, 2026, in San Diego.
February 17, 2026
Avanti Biosciences has been selected as a Hello Tomorrow Deep Tech Pioneer in the 11th Hello Tomorrow Challenge, recognized from 4,800+ applications across 108 countries. The company is now in the running to become a Finalist, with notification expected by mid-March 2026. If selected as a Finalist, Avanti will be invited to pitch at the Hello Tomorrow Summit in Amsterdam on June 11-12, 2026.
February 10, 2026
Avanti Biosciences has been selected to present at Biocom's sold-out Global Partnering & Investor Conference (GPIC), February 24–26, 2026, at The Lodge at Torrey Pines, San Diego. The company will present its clinical development strategy for ABI-171, the first therapy to demonstrate disease reversal in idiopathic pulmonary fibrosis (IPF).
December 2025
Avanti Biosciences has been awarded the NHLBI Catalyze Program by the National Heart, Lung, and Blood Institute (NIH). The program provides funding and regulatory support for IND-enabling studies, GMP manufacturing, and clinical trial preparation for ABI-171 in idiopathic pulmonary fibrosis (IPF).
December 2025
The U.S. Food and Drug Administration (FDA) has granted Avanti Biosciences a Pre-IND Type B meeting (PIND 180251) to discuss the clinical development plan for ABI-171 in idiopathic pulmonary fibrosis. Written responses are expected in March 2026.
July 18, 2024
Received orphan-drug designation from the FDA for our lead molecule, ABI-171, in the treatment of idiopathic pulmonary fibrosis (IPF).
July 23, 2023
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK (1R43DK134232-01A1) for the development of new therapies for the treatment of liver diseases in collaboration with Ohio State University (Professor Richard Bruno)
May 5, 2019
Avanti Biosciences has been awarded the second phase of the fast-track SBIR grants from the NIA for its work on Alzheimer's Disease.
July 30, 2018
Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK for the development of new therapies for the treatment of Hyperinsulinemia Hyperammonemia Syndrome in collaboration with the Children's Hospital of Philadelphia (CHOP)
May 1, 2018
Avanti Biosciences open new operations in the JLAB San Diego.
August 15, 2017
Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s Disease
October 8, 2015